ArticleFrontiers in clinical diabetes and healthcare2026
Bone morphogenetic protein 4-associated mitochondrial dysfunction in diabetic nephropathy involves Parkin downregulation.
Article in Frontiers in clinical diabetes and healthcare, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic nephropathy (DN) is characterized by mesangial expansion and mitochondrial dysfunction. Although bone morphogenetic protein 4 (BMP4) is a pro-fibrotic factor in DN, its role in mesangial mitochondrial homeostasis remains unclear. This study investigated whether a decrease in Parkin is involved in mitochondria-related abnormalities following BMP4 stimulation. Methods: Renal tissues from streptozotocin (STZ)-induced diabetic mice were subjected to biochemical, histological, and molecular analyses. Results: In STZ-induced diabetic mice, mesangial expansion was accompanied by mitochondrial abnormalities, increased BMP4 expression, diminished mtDNA copy number, and decreased expression of Parkin and related genes. In cultured mesangial cells, BMP4 stimulation was accompanied by a decrease in Parkin expression and reduced mitochondria-related indices, including decreased expression of mitochondrial function-related genes, reduced ATP production, and loss of membrane potential. The BMP4-induced changes in gene expression and mitochondrial functional indices were ameliorated by ALK inhibition. Furthermore, Parkin overexpression ameliorated BMP4-induced decreases in gene expression and mitochondrial functional indices. Conclusion: These findings suggest that decreased Parkin expression associated with BMP4 stimulation may be one of the molecular alterations contributing to mitochondria-related abnormalities in mesangial cells. Disrupted mitochondrial homeostasis accompanied by decreased Parkin expression may represent a candidate therapeutic pathway in DN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.